Please login to the form below

Not currently logged in
Email:
Password:

IDO inhibitor

This page shows the latest IDO inhibitor news and features for those working in and with pharma, biotech and healthcare.

Another R&D flop for Incyte, but Jakafi keeps delivering

Another R&D flop for Incyte, but Jakafi keeps delivering

Incyte is still trying to recover from the mauling it took after its IDO inhibitor epacadostat for cancer failed earlier this year, and yesterday wrote off another programme in ... JAK1/JAK2 inhibitor Jakafi – given in combination with corticosteroids

Latest news

  • BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

    IDO1 inhibitor given alongside Opdivo, BMS’ CTLA4 inhibitor Yervoy (ipilimumab), other marketed cancer drugs and LAG-3 candidate relatlimab. ... Meanwhile another study of epacadostat with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will also

  • NewLink pancreatic cancer vaccine flunks phase III test NewLink pancreatic cancer vaccine flunks phase III test

    efforts on its IDO checkpoint inhibitor programme. ... The IDO inhibitor pipeline is currently led by indoximod, which is in phase II for breast cancer (in combination with taxane drugs docetaxel and paclitaxel) and prostate cancer (in combination with

  • BMS buys immunotherapy specialist Flexus in $1.2bn deal BMS buys immunotherapy specialist Flexus in $1.2bn deal

    With the addition of a potentially best-in-class IDO1 inhibitor and the broad IDO/TDO programmes, Bristol-Myers Squibb will accelerate its ability to explore numerous immunotherapeutic approaches across tumour ... the development of our potentially

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Meanwhile, despite the mixed results for checkpoint inhibitor combinations to date, there’s no let-up in the pursuit of new cocktail recipes. ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor epacadostat bombed when paired with Keytruda in a

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    F001287, IDO1 inhibitor IDO/TDO discovery programme - immuno-oncology. Corporate acquisition. 1, 250. ... Abbreviations:. IDO, Indoleamine-2, 3-dioxygenase; TDO, Tryptophan-2, 3- dioxygenase. COPD, chronic obstructive pulmonary disease.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...